Biomarkers as prognostic factors in endometrial cancer.

Dobrzycka, Bożena; Terlikowski, S

doi:10.2478/v10042-10-0061-8

Cited by 18 publications

(10 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well known that angiogenesis plays a critical role in the progression of endometrial cancer [21]. One of the most powerful pro-angiogenic factors, which are involved in the angiogenesis during type 1 endometrial cancer, is vascular endothelial growth factor (VEGF) [12].…”

Section: Proteinmentioning

confidence: 99%

Comparative characteristics of the transcriptional activity of CDH1, CTNNB1, VEGFA genes and expression of proteins E-cadherin, β-catenin and VEGFA, coded by these genes in metastatic and non-metastatic endometrioid endometrial carcinoma

2016

View full text Add to dashboard Cite

The violation of Wnt-signaling pathway and cyclic neoangiogenesis is early events in endometrial carcinogenesis. In this process an important role is played by epigenetic modifi cations and mutations of CDH1, CTNNB1, VEGFA genes, followed by expression violations of E-cadherin, β-catenin, VEGFA encoded by them.The aim. To study the expression levels of mRNA of CDH1, CTNNB1, VEGFA genes and the expression levels of E-cadherin, β-catenin, VEGFA in non-metastatic endometrioid endometrial carcinoma (EEC) and in EEC with metastases to regional lymph nodes. Materials and methods.Immunohistochemical study of invasive рТ 1-4 N 0 M x endometrioid endometrial carcinoma (EEC) (n=56; age -42-83 years), invasive рТ 1-4 N 1-2 M x EEC (n=30; age -48-79 years), samples of normal proliferative endometrium (PE) (n=30; age -41-62 years) was performed. Molecular-genetic study of invasive рТ 1-4 N 0 M x EEC (n=10; age -45-67 years), invasive рТ 1-4 N 1-2 M x EEC (n=10; age -44-63 years), samples of PE (n=10; age -46-59 years) was performed.Results. EEC is characterized by the lower mRNA expression level of CDH1 gene and by the higher mRNA expression levels of CTNNB1, VEGFA genes in comparison with the PE. E-cadherin expression level is 32.6 % lower in non-metastatic EEC and also is 58.10 % lower in metastatic EEC in comparison with the PE. β-catenin expression level is 32.56 % lower in non-metastatic EEC and also is 58.11 % lower in metastatic EEC in comparison with the PE. VEGFA expression level is 27.72 % higher in non-metastatic EEC and also is 17.87 % higher in metastatic EEC in comparison with the PE. There is lower β-catenin expression level in metastatic EEC in comparison with non-metastatic EEC. Non-metastatic and metastatic EEC is characterized by the direct medium connections between the mRNA expression levels of CTNNB1 and VEGFA genes (γ=0.44), between the mRNA expression level of CTNNB1 gene and VEGFA expression level in the tumor (γ=0.37).Conclusions. These changes contribute to tumor growth, invasion and metastasis.Порівняльна характеристика транскрипційної активності генів CDH1, CTNNB1, VEGFA та експресії кодованих ними білків Е-кадгерину, β-катеніну та VEGFA в метастатичній ендометріоїдній аденокарциномі тіла матки і в аденокарциномі без метастазів В. О. Туманський, О. В. Чепець, О. М. КамишнийУ канцерогенезі рака ендометрію ранніми подіями є порушення Wnt-сигнального шляху та циклічного ангіогенезу. Важли-ву роль при цьому відіграють епігенетичні модифікації генів і мутації генів CDH1, CTNNB1, VEGFА з дальшим порушенням експресії кодованих ними протеїнів -Е-кадгерину, β-катеніну, VEGFА.Мета роботи -вивчити молекулярно-генетичними методами рівень експресії мРНК генів CDH1, CTNNB1, VEGFА, імуно-гістохімічним методом -рівні експресіі Е-кадгерину, β-катеніну, VEGFA в ендометріоїдній аденокарциномі ендометрію без метастазів і з метастазами в регіонарні лімфовузли.Матеріали та методи. Імуногістохімічним методом вивчена інвазивна рТ 1-4 N 0 M х G 1-3 ендометріоїдна аденокарцинома ен-дометрію (ЕАЕ) (n=56; вік -42-83 роки), ...

show abstract

Section: Proteinmentioning

confidence: 99%

Comparative characteristics of the transcriptional activity of CDH1, CTNNB1, VEGFA genes and expression of proteins E-cadherin, β-catenin and VEGFA, coded by these genes in metastatic and non-metastatic endometrioid endometrial carcinoma

2016

View full text Add to dashboard Cite

show abstract

“…Mainly, it has serous or clear-cell morphology. This type is related to high-grade tumors and poor prognosis [2][3][4]. Moreover, Ryan et al summarized molecular pathogenesis of EC.…”

Section: Endometrial Cancermentioning

confidence: 99%

The evaluation of involvement of angiotensin II, its receptors, and androgen receptor in endometrial cancer

Matysiak

Ochędalski

Piastowska-Ciesielska

2014

Gynecological Endocrinology

View full text Add to dashboard Cite

Endometrial cancer (EC) is the most common gynecological malignancy. Alterations of angiogenic factors including angiotensin (AngII) or VEGF are observed in EC. Expression of angiotensin receptor 1 (AT1) is correlated with EC. Moreover, the expression of VEGF is up-regulated by AngII. Androgens are involved in the pathogenesis of EC. Genetic variations in androgen receptor (AR) gene may increase EC risk. This review proved strong correlation among EC, AngII, its receptors and AR, where AT influence on AR and, as a result, induce the expression of genes related to carcinogenesis.

show abstract

“…Although most women diagnosed with endometrial cancer present with an early stage disease confined to the uterus, metastatic disease is identified in a significant percentage of cases when comprehensive staging is performed [5]. The poor sensitivity of imaging modalities in detecting deep myometrial invasion and extrauterine disease suggests the role of endometrial cancer specific serum biomarkers in assisting with the preoperative stratification of patients into risk groups, surgical planning and prognostication [6][7][8]. However, there are no nomograms for predicting the risk of endometrial cancer; therefore, our primary goal is to develop a new scoring system, called the risk of endometrial malignancy (REM) score, capable to classify patients with endometrial abnormalities into high-or low-risk groups for endometrial cancer using clinical, ultrasound, and serum markers features.…”

Section: Introductionmentioning

confidence: 99%

Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy

Dobrzycka

Maćkowiak-Matejczyk²,

Terlikowska

et al. 2016

Advances in Medical Sciences

View full text Add to dashboard Cite

Biomarkers as prognostic factors in endometrial cancer.

Cited by 18 publications

References 37 publications

Comparative characteristics of the transcriptional activity of CDH1, CTNNB1, VEGFA genes and expression of proteins E-cadherin, β-catenin and VEGFA, coded by these genes in metastatic and non-metastatic endometrioid endometrial carcinoma

Comparative characteristics of the transcriptional activity of CDH1, CTNNB1, VEGFA genes and expression of proteins E-cadherin, β-catenin and VEGFA, coded by these genes in metastatic and non-metastatic endometrioid endometrial carcinoma

The evaluation of involvement of angiotensin II, its receptors, and androgen receptor in endometrial cancer

Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy

Contact Info

Product

Resources

About